Vebreltinib
Sponsors
Avistone Biotechnology Co., Ltd., Shanghai Pulmonary Hospital, Shanghai, China, National Cancer Center, China, Second Affiliated Hospital, School of Medicine, Zhejiang University, Shanghai Chest Hospital
Conditions
Clear Cell Sarcoma (CCS)Lung NeoplasmsNon-Small-Cell Lung CancerPotentially Resectable MET-altered Non-Small Cell Lung Cancer
Phase 1
Vebreltinib Plus PLB1004 in EGFR-mutated, Advanced NSCLC With MET Amplification or MET Overexpression Following EGFR-TKI
RecruitingNCT06343064
Start: 2023-06-13End: 2026-12-31Target: 156Updated: 2025-05-21
Vebreltinib Plus Furmonertinib in Patients With EGFR-mutated Advanced Non-small Cell Lung Cancer and High PD-L1 Expression
RecruitingNCT07655622
Start: 2026-07-03End: 2029-06-03Target: 45Updated: 2026-06-18
Phase 2
Vebreltinib Plus PLB1004 as the First-line Therapy for Patients With EGFRm+/MET+ Locally Advanced or Metastatic NSCLC.
RecruitingNCT06574347
Start: 2024-08-07End: 2027-07-31Target: 120Updated: 2025-05-21
Vebreltinib for Neoadjuvant in MET-altered Stage IIIA-IIIB (N2) Non-small Cell Lung Cancer (NSCLC)
Not yet recruitingNCT06644313
Start: 2024-11-01End: 2029-11-01Target: 31Updated: 2024-10-16
Combination of Vebreltinib and Osimertinib in Patients with EGFR 21 L858R Mutation Advanced NSCLC
Active, not recruitingNCT06827145
Start: 2024-10-14End: 2028-09-30Target: 30Updated: 2025-02-14
Vebreltinib for Advanced or Metastatic CCS
RecruitingNCT07153887
Start: 2025-09-30End: 2027-07-15Target: 30Updated: 2025-09-30
Vebreltinib Plus Chemotherapy as First-line Treatment for MET-overexpressing NSCLC
Not yet recruitingNCT07549061
Start: 2026-03-30End: 2028-12-30Target: 19Updated: 2026-04-29